NOVEL CD4+ T CELL COSTIMULATORY MOLECULE IN EAE
NOVEL CD4+ T CELL COSTIMULATORY MOLECULE IN EAE
批准号:
2460652
负责人:
Andrew D Weinberg
金额:
$17.23万
依托单位国家:
美国
项目类别:
财政年份:
1995
资助国家:
美国
项目状态:
已结题
起止时间:
1995-09-30 至 1999-07-31
中文摘要
描述(改编自研究者摘要):在
检查从具有EAE临床体征的大鼠中分离的细胞,
主要研究者注意到细胞表面标记物的存在
(0X 40)在CNS驻留的T细胞上。 这种抗原是TNF-R的一个成员,
家族,在大多数情况下只表达在MBP特异性T细胞上,
细胞,主要是那些已经归巢到中枢神经系统,导致
首席研究员在这个新的R 01中提出,OX 40是关键
EAE效应细胞表面分子。他的计划是评估
OX 40表达的生物学意义,使用抗OX 40试剂
确定炎症部位最近激活的T细胞,
通过它们的OX 40受体共刺激这些细胞,以鉴定OX 40
靶CNS组织内的配体,以制备免疫毒素和用途
在脱髓鞘复发性EAE模型中,表征人OX-40
在MS中的表达,最后,以表征体内意义
通过敲除这种受体的小鼠,在CD 4 T细胞上产生OX 40。
T细胞上EAE选择性标志物的鉴定是一个非常重要的方法。
考虑到免疫抑制剂的最新发展水平,
MS的治疗,以及本研究中提出的特定方法
申请是合理的,及时的,在技能范围内,
这个调查员。
英文摘要
DESCRIPTION (Adapted from Investigator's abstract): In the course of
examining cells isolated from rats with clinical signs of EAE, the
principal investigator noted the presence of a cell surface marker
(OX40) on CNS-resident T-cells. This antigen, a member of the TNF-R
family, was for the most part exclusively expressed on MBP-specific T-
cells and primarily on those that had homed to the CNS, leading the
principal investigator to propose in this new R01 that OX40 is key
surface molecule on EAE-effector cells. His plan is to assess the
biological significance of the OX40 expression, using anti-OX40 reagents
to define recently activated T-cells in the inflammatory site, to
costimulate these cells via their OX40 receptor, to identify the OX40
ligand within the target CNS tissue, to prepare an immunotoxin and use
it in a demyelinating relapsing EAE model, to characterize human OX-40
expression in MS, and finally, to characterize the in vivo significance
of OX40 on CD4 T-cells by creating a mouse knockout for this receptor.
The identification of EAE-selective markers on T-cells is a very
worthwhile goal, given the state of the art in immunosuppressive
therapies for MS, and the particular approach presented in this
application is rational, timely, and within the scope of the skills of
this investigator.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The Importance of T cell Survival in Tumor Immunity
-
批准号:7267310
-
项目类别:
-
资助金额:$27.04万
-
财政年份:2007
-
负责人:Andrew D Weinberg
-
依托单位:
The Importance of T cell Survival in Tumor Immunity
-
批准号:8020895
-
项目类别:
-
资助金额:$26.23万
-
财政年份:2007
-
负责人:Andrew D Weinberg
-
依托单位:
The Importance of T cell Survival in Tumor Immunity
-
批准号:7759639
-
项目类别:
-
资助金额:$27.04万
-
财政年份:2007
-
负责人:Andrew D Weinberg
-
依托单位:
The Importance of T cell Survival in Tumor Immunity
-
批准号:7391821
-
项目类别:
-
资助金额:$27.04万
-
财政年份:2007
-
负责人:Andrew D Weinberg
-
依托单位:
The Importance of T cell Survival in Tumor Immunity
-
批准号:7555038
-
项目类别:
-
资助金额:$27.04万
-
财政年份:2007
-
负责人:Andrew D Weinberg
-
依托单位:
To Understand/Augment OX40-mediated Tumor Immunotherapy
-
批准号:8070502
-
项目类别:
-
资助金额:$30.63万
-
财政年份:2003
-
负责人:Andrew D Weinberg
-
依托单位:
To Understand/Augment OX40-mediated Tumor Immunotherapy
-
批准号:7089030
-
项目类别:
-
资助金额:$30.92万
-
财政年份:2003
-
负责人:Andrew D Weinberg
-
依托单位:
To Understand/Augment OX40-mediated Tumor Immunotherapy
-
批准号:7227428
-
项目类别:
-
资助金额:$30.02万
-
财政年份:2003
-
负责人:Andrew D Weinberg
-
依托单位:
To Understand/Augment OX40-mediated Tumor Immunotherapy
-
批准号:6762363
-
项目类别:
-
资助金额:$31.66万
-
财政年份:2003
-
负责人:Andrew D Weinberg
-
依托单位:
To Understand/Augment OX40-mediated Tumor Immunotherapy
-
批准号:8465111
-
项目类别:
-
资助金额:$28.79万
-
财政年份:2003
-
负责人:Andrew D Weinberg
-
依托单位:
To Understand/Augment OX40-mediated Tumor Immunotherapy
-
批准号:6676730
-
项目类别:
-
资助金额:$31.66万
-
财政年份:2003
-
负责人:Andrew D Weinberg
-
依托单位:
To Understand/Augment OX40-mediated Tumor Immunotherapy
-
批准号:7860496
-
项目类别:
-
资助金额:$31.57万
-
财政年份:2003
-
负责人:Andrew D Weinberg
-
依托单位:
To Understand/Augment OX40-mediated Tumor Immunotherapy
-
批准号:7755849
-
项目类别:
-
资助金额:$31.57万
-
财政年份:2003
-
负责人:Andrew D Weinberg
-
依托单位:
To Understand/Augment OX40-mediated Tumor Immunotherapy
-
批准号:8255363
-
项目类别:
-
资助金额:$30.63万
-
财政年份:2003
-
负责人:Andrew D Weinberg
-
依托单位:
To Understand/Augment OX40-mediated Tumor Immunotherapy
-
批准号:6911614
-
项目类别:
-
资助金额:$31.66万
-
财政年份:2003
-
负责人:Andrew D Weinberg
-
依托单位:
USING NOVEL TNF RECEPTORS TO ENHANCE IMMUNOTHERAPY
-
批准号:6377145
-
项目类别:
-
资助金额:$17.9万
-
财政年份:1999
-
负责人:Andrew D Weinberg
-
依托单位:
USING NOVEL TNF RECEPTORS TO ENHANCE IMMUNOTHERAPY
-
批准号:2839714
-
项目类别:
-
资助金额:$16.87万
-
财政年份:1999
-
负责人:Andrew D Weinberg
-
依托单位:
USING NOVEL TNF RECEPTORS TO ENHANCE IMMUNOTHERAPY
-
批准号:6174294
-
项目类别:
-
资助金额:$17.38万
-
财政年份:1999
-
负责人:Andrew D Weinberg
-
依托单位:
USING NOVEL TNF RECEPTORS TO ENHANCE IMMUNOTHERAPY
-
批准号:6513553
-
项目类别:
-
资助金额:$18.44万
-
财政年份:1999
-
负责人:Andrew D Weinberg
-
依托单位:
NOVEL CD4+ T CELL COSTIMULATORY MOLECULE IN EAE
-
批准号:2750939
-
项目类别:
-
资助金额:$17.91万
-
财政年份:1995
-
负责人:Andrew D Weinberg
-
依托单位:
国内基金
海外基金
基于DNA甲基化交互网络的癌症hallmark挖掘及其在癌症转移biomarker筛选中的应用
-
批准号:61602201
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2016
-
负责人:周雄辉
-
依托单位:
血清miRNAs成为一种新的biomarker在PD诊断中的价值和LRRK2基因调控的机制研究
-
批准号:81170309
-
项目类别:面上项目
-
资助金额:50.0万元
-
批准年份:2011
-
负责人:颜桥
-
依托单位:
非小细胞肺癌Biomarker的Imaging MS研究新方法
-
批准号:30672394
-
项目类别:面上项目
-
资助金额:30.0万元
-
批准年份:2006
-
负责人:陆豪杰
-
依托单位: